Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Reza Yarani, Kamran Mansouri, Hamid R. Mohammadi-Motlagh, Azadeh Mahnam & Mohammad S. Emami Aleagha. (2013) In vitro inhibition of angiogenesis by hydroalcoholic extract of oak (Quercus infectoria) acorn shell via suppressing VEGF, MMP-2, and MMP-9 secretion. Pharmaceutical Biology 51:3, pages 361-368.
Read now
Read now
Peter Stopfer, Karin Rathgen, Daniel Bischoff, Silke Lüdtke, Kristell Marzin, Rolf Kaiser, Klaus Wagner & Thomas Ebner. (2011) Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 41:4, pages 297-311.
Read now
Read now
Susan E Pories & Gerburg M Wulf. (2010) Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. Breast Cancer: Targets and Therapy 2, pages 37-44.
Read now
Read now
Martin H Fenner, Gernot Beutel & Viktor Grünwald. (2008) Targeted therapies for patients with germ cell tumors. Expert Opinion on Investigational Drugs 17:4, pages 511-522.
Read now
Read now
Articles from other publishers (57)
Jeffrey J. Jackson, Grant M. Shibuya, Buvana Ravishankar, Lavanya Adusumilli, Delia Bradford, Dirk G. Brockstedt, Cyril Bucher, Minna Bui, Cynthia Cho, Christoph Colas, Gene Cutler, Adrian Dukes, Xinping Han, Dennis X. Hu, Scott Jacobson, Paul D. Kassner, George E. Katibah, Michelle Yoo Min Ko, Urvi Kolhatkar, Paul R. Leger, Anqi Ma, Lisa Marshall, Jack Maung, Andrew A. Ng, Akinori Okano, Deepa Pookot, Daniel Poon, Chandru Ramana, Maureen K. Reilly, Omar Robles, Jacob B. Schwarz, Anton A. Shakhmin, Hunter P. Shunatona, Raashi Sreenivasan, Parcharee Tivitmahaisoon, Mengshu Xu, Thant Zaw, David J. Wustrow & Mikhail Zibinsky. (2022) Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy. Journal of Medicinal Chemistry 65:19, pages 12895-12924.
Crossref
Crossref
Chuda Chittasupho, Kantalada Kengtrong, Supawan Chalermnithiwong & Narong Sarisuta. (2020) Anti-angiogenesis by dual action of R5K peptide conjugated itraconazole nanoparticles. AAPS PharmSciTech 21:3.
Crossref
Crossref
Enrica Capelletto, Maria Rita Migliorino, Alessandro Morabito, Rita Chiari, Francesco Grossi, Marcello Tiseo, Francesco Di Costanzo, Angelo Delmonte, Gianpiero Romano, Domenico Galetta, Vieri Scotti, Vanesa Gregorc, Salvatore Pisconti, Giovanni Luca Ceresoli, Alessandro Del Conte, Libero Ciuffreda, Ida Colantonio, Emilio Bria, Serena Ricciardi, Anna Manzo, Giulio Metro, Anna Maria Morelli, Rossana Critelli, Maria Vittoria Pacchiana, Ilaria Stura, Giuseppe Migliaretti & Silvia Novello. (2019) Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. Lung Cancer 134, pages 210-217.
Crossref
Crossref
Marianne A. Grant & Aly Karsan. 2018. Hematology. Hematology
1843
1856.e6
.
P. S. Sushma. 2018. Role of Tyrosine Kinases in Gastrointestinal Malignancies. Role of Tyrosine Kinases in Gastrointestinal Malignancies
15
28
.
Girolamo Ranieri, Cristina Ferrari, Alessandra Di Palo, Ilaria Marech, Mariangela Porcelli, Gianmarco Falagario, Fabiana Ritrovato, Luigi Ramunni, Margherita Fanelli, Giuseppe Rubini & Cosmo Damiano Gadaleta. (2017) Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study. International Journal of Molecular Sciences 18:7, pages 1458.
Crossref
Crossref
Luis Corrales, Amanda Nogueira, Francesco Passiglia, Angela Listi, Christian Caglevic, Marco Giallombardo, Luis Raez, Edgardo Santos & Christian Rolfo. (2017) Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. Frontiers in Medicine 4.
Crossref
Crossref
Francesco Torino, Roberta Sarmiento, Raffaelle Longo & Giampietro Gasparini. 2017. The Molecular Basis of Human Cancer. The Molecular Basis of Human Cancer
757
769
.
Ming Sun, Na Lv, Zeng Li, Qiru Xiong, Liang Xu & Zongsheng Yin. (2015) N-(4-(quinazolin-2-yl)phenyl)benzamide derivatives with potent anti-angiogenesis activities: synthesis and evaluation. Journal of the Iranian Chemical Society 13:4, pages 753-761.
Crossref
Crossref
B. Kuhnast, A. El Hadri, R. Boisgard, F. Hinnen, S. Richard, A. Caravano, V. Nancy-Portebois, M. Petitou, B. Tavitian & F. Dollé. (2016) Synthesis, radiolabeling with fluorine-18 and preliminary in vivo evaluation of a heparan sulphate mimetic as potent angiogenesis and heparanase inhibitor for cancer applications. Organic & Biomolecular Chemistry 14:6, pages 1915-1920.
Crossref
Crossref
Silvia Novello, Rolf Kaiser, Anders Mellemgaard, Jean-Yves Douillard, Sergey Orlov, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao, Jos? Barrueco, Birgit Gaschler-Markefski, Ingolf Griebsch, Michael Palmer & Martin Reck. (2015) Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. European Journal of Cancer 51:3, pages 317-326.
Crossref
Crossref
Avinash KambadakoneSam S. YoonTae-Min KimDaniel L. KarlDan G. DudaThomas F. DeLaneyDushyant V. Sahani. (2015) CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas: Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression. American Journal of Roentgenology 204:1, pages W11-W18.
Crossref
Crossref
Naoyuki Fujita, Takatsugu Okegawa, Yuichi Terado, Mitsuhiro Tambo, Eiji Higashihara & Kikuo Nutahara. (2014) Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma. BMC Research Notes 7:1.
Crossref
Crossref
Guangcheng Wang, Fang Wang, Dong Cao, Yibin Liu, Ronghong Zhang, Haoyu Ye, Xiuxia Li, Lin He, Zhuang Yang, Liang Ma, Aihua Peng, Mingli Xiang, Yuquan Wei & Lijuan Chen. (2014) Synthesis, structure–activity relationships and biological evaluation of barbigerone analogues as anti-proliferative and anti-angiogenesis agents. Bioorganic & Medicinal Chemistry Letters 24:14, pages 3158-3163.
Crossref
Crossref
Erin J. Sheridan, Christopher J. D. Austin, Jade B. Aitken, Stefan Vogt, Katrina A. Jolliffe, Hugh H. Harris & Louis M. Rendina. (2013) Synchrotron X-ray fluorescence studies of a bromine-labelled cyclic RGD peptide interacting with individual tumor cells. Journal of Synchrotron Radiation 20:2, pages 226-233.
Crossref
Crossref
Yeo‐Jung Kim, Hae‐June Lee, Tae‐Min Kim, T.S. Karin Eisinger‐Mathason, Alexia Y. Zhang, Benjamin Schmidt, Daniel L. Karl, Michael S. Nakazawa, Peter J. Park, M. Celeste Simon & Sam S. Yoon. (2012) Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia‐inducible factor 1α. International Journal of Cancer 132:1, pages 29-41.
Crossref
Crossref
Vito Ferro, Ligong Liu, Ken D. Johnstone, Norbert Wimmer, Tomislav Karoli, Paul Handley, Jessica Rowley, Keith Dredge, Cai Ping Li, Edward Hammond, Kat Davis, Laura Sarimaa, Job Harenberg & Ian Bytheway. (2012) Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis. Journal of Medicinal Chemistry 55:8, pages 3804-3813.
Crossref
Crossref
Jiachang Gong, Jinping Gan & Ramaswamy A. Iyer. (2012) Identification of the Oxidative and Conjugative Enzymes Involved in the Biotransformation of Brivanib. Drug Metabolism and Disposition 40:1, pages 219-226.
Crossref
Crossref
Khanitha Pudhom, Thanesuan Nuanyai, Kiminori Matsubara & Tirayut Vilaivan. (2012) Antiangiogenic activity of 3,4-seco-cycloartane triterpenes from Thai Gardenia spp. and their semi-synthetic analogs. Bioorganic & Medicinal Chemistry Letters 22:1, pages 512-517.
Crossref
Crossref
Blake T. Aftab, Irina Dobromilskaya, Jun O. Liu & Charles M. Rudin. (2011) Itraconazole Inhibits Angiogenesis and Tumor Growth in Non–Small Cell Lung Cancer. Cancer Research 71:21, pages 6764-6772.
Crossref
Crossref
Ramaswamy Bhuvaneswari, Gan Yik Yuen, Soo Khee Chee & Malini Olivo. (2011) Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model. Lasers in Surgery and Medicine 43:7, pages 651-662.
Crossref
Crossref
Lidia Boccardi, Daniela Cardinale, Maurizio Civelli, Chiara Lestuzzi, Carlo Materazzo, Nicola Maurea, Ines Monte, Stefano Oliva, Patrizia Piotti, Giuseppina Quattrocchi, Elisabetta Rossi & Giuseppe Toglia. (2011) Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo. Journal of Cardiovascular Echography 21:1, pages 32-41.
Crossref
Crossref
Mokdad Mezna, George Kontopidis & Campbell McInnes. 2011. Protein Kinases as Drug Targets. Protein Kinases as Drug Targets
229
270
.
Qing-feng Xiang, Fang Wang, Xiao-dong Su, Yong-ju Liang, Li-sheng Zheng, Yan-jun Mi, Wei-qiang Chen & Li-wu Fu. (2011) Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cellular Oncology 34:1, pages 33-44.
Crossref
Crossref
Partha S. Bhattacharjee, Tashfin S. Huq, Tarun K. Mandal, Richard A. Graves, Syed Muniruzzaman, Christian Clement, Harris E. McFerrin & James M. Hill. (2011) A Novel Peptide Derived from Human Apolipoprotein E Is an Inhibitor of Tumor Growth and Ocular Angiogenesis. PLoS ONE 6:1, pages e15905.
Crossref
Crossref
Sergio Bracarda, Joaquim Bellmunt, Bohuslav Melichar, Sylvie Négrier, Emilio Bajetta, Alain Ravaud, Vesna Sneller & Bernard Escudier. (2011) Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU International 107:2, pages 214-219.
Crossref
Crossref
Roderich Süssmuth, Jane Müller, Hans von Döhren & István Molnár. (2011) Fungal cyclooligomerdepsipeptides: From classical biochemistry to combinatorial biosynthesis. Nat. Prod. Rep. 28:1, pages 99-124.
Crossref
Crossref
Yoon-Jin Lee, Daniel L. Karl, Ugwuji N. Maduekwe, Courtney Rothrock, Sandra Ryeom, Patricia A. D'Amore & Sam S. Yoon. (2010) Differential Effects of VEGFR-1 and VEGFR-2 Inhibition on Tumor Metastases Based on Host Organ Environment. Cancer Research 70:21, pages 8357-8367.
Crossref
Crossref
Archontoula Stoffel. (2010) Targeted Therapies for Solid Tumors. BioDrugs 24:5, pages 303-316.
Crossref
Crossref
Donald J. AbrahamRobert H. Bradbury. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
295
344
.
Torsten Falk, Robert T. Gonzalez & Scott J. Sherman. (2010) The Yin and Yang of VEGF and PEDF: Multifaceted Neurotrophic Factors and Their Potential in the Treatment of Parkinson’s Disease. International Journal of Molecular Sciences 11:8, pages 2875-2900.
Crossref
Crossref
Shimon Lecht, Hadar Arien-Zakay, Martin Kohan, Peter I. Lelkes & Philip Lazarovici. (2010) Angiostatic effects of K252a, a Trk inhibitor, in murine brain capillary endothelial cells. Molecular and Cellular Biochemistry 339:1-2, pages 201-213.
Crossref
Crossref
K. Dredge, E. Hammond, K. Davis, C. P. Li, L. Liu, K. Johnstone, P. Handley, N. Wimmer, T. J. Gonda, A. Gautam, V. Ferro & I. Bytheway. (2009) The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Investigational New Drugs 28:3, pages 276-283.
Crossref
Crossref
Jihong Zhang, Yingchun Zheng, Yunxiu Wang & Haixia Tong. (2010) The Studies on the Correlation for Gene Expression of Tyrosine-kinase Receptors and Vascular Endothelial Growth Factor in Human Neuroblastomas. Journal of Pediatric Hematology/Oncology 32:3, pages 180-184.
Crossref
Crossref
Gerald W. Prager, Eva-Maria Lackner, Maria-Theresa Krauth, Matthias Unseld, Marina Poettler, Sylvia Laffer, Sabine Cerny-Reiterer, Wolfgang Lamm, Gabriela V. Kornek, Bernd R. Binder, Christoph C. Zielinski & Peter Valent. (2010) Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. Molecular Oncology 4:2, pages 150-160.
Crossref
Crossref
Shayne Cox GadPeter J. Bugelski, Clifford Sachs, Joel Cornacoff, Pauline Martin & George Treacy. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia.
Ken D. Johnstone, Tomislav Karoli, Ligong Liu, Keith Dredge, Elizabeth Copeman, Cai Ping Li, Kat Davis, Edward Hammond, Ian Bytheway, Edmund Kostewicz, Francis C. K. Chiu, David M. Shackleford, Susan A. Charman, William N. Charman, Job Harenberg, Thomas J. Gonda & Vito Ferro. (2010) Synthesis and Biological Evaluation of Polysulfated Oligosaccharide Glycosides as Inhibitors of Angiogenesis and Tumor Growth. Journal of Medicinal Chemistry 53:4, pages 1686-1699.
Crossref
Crossref
Jeffrey L. Brown, Z. Alexander Cao, Maria Pinzon-Ortiz, Jane Kendrew, Corinne Reimer, Shenghua Wen, Joe Q. Zhou, Mohammad Tabrizi, Steve Emery, Brenda McDermott, Lourdes Pablo, Patricia McCoon, Vahe Bedian & David C. Blakey. (2010) A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models. Molecular Cancer Therapeutics 9:1, pages 145-156.
Crossref
Crossref
Carie S. FacemireAndrew B. NixonRobert GriffithsHerbert HurwitzThomas M. Coffman. (2009) Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression. Hypertension 54:3, pages 652-658.
Crossref
Crossref
Roy S. HerbstDavid HongLinnea ChapRazelle KurzrockEdward JacksonJeffrey M. SilvermanErik RasmussenYu-Nien SunDon ZhongYuying C. HwangJeffrey L. EvelhochJonathan D. OlinerNgocDiep LeLee S. Rosen. (2009) Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors. Journal of Clinical Oncology 27:21, pages 3557-3565.
Crossref
Crossref
Bernard EscudierTim EisenWalter M. StadlerCezary SzczylikStéphane OudardMichael StaehlerSylvie NegrierChristine ChevreauApurva A. DesaiFrédéric RollandTomasz DemkowThomas E. HutsonMartin GoreSibyl AndersonGloria HofilenaMinghua ShanCarol PenaChetan LathiaRonald M. Bukowski. (2009) Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Journal of Clinical Oncology 27:20, pages 3312-3318.
Crossref
Crossref
Vincent T. DeVitaJr.Jr. & Edward Chu. (2008) A History of Cancer Chemotherapy. Cancer Research 68:21, pages 8643-8653.
Crossref
Crossref
Charles Elson & Huanbiao Mo. 2008. Tocotrienols. Tocotrienols
185
207
.
André M. van RijGregory T. JonesB. Geraldine HillMohammad AmerIan A. ThomsonRoss A. PettigrewStephen G.K. Packer. (2008) Mechanical Inhibition of Angiogenesis at the Saphenofemoral Junction in the Surgical Treatment of Varicose Veins. Circulation 118:1, pages 66-74.
Crossref
Crossref
Frank Hilberg, Gerald J. Roth, Martin Krssak, Susanna Kautschitsch, Wolfgang Sommergruber, Ulrike Tontsch-Grunt, Pilar Garin-Chesa, Gerd Bader, Andreas Zoephel, Jens Quant, Armin Heckel & Wolfgang J. Rettig. (2008) BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy. Cancer Research 68:12, pages 4774-4782.
Crossref
Crossref
Tadhg P. BegleyFlashman Emily, Loenarz Christoph & Christopher J. Schofield. 2007. Wiley Encyclopedia of Chemical Biology. Wiley Encyclopedia of Chemical Biology.
Nizar A. Mullani, Roy S. Herbst, Roger G. O'Neil, K. Lance Gould, Bruce J. Barron & James L. Abbruzzese. (2008)
Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass
18
F-FDG Uptake: A Comparison with
15
O-Labeled Water-Measured Blood Flow
. Journal of Nuclear Medicine 49:4, pages 517-523.
Crossref
Crossref
Pamela H. Carney & Cathy L. Ollom. (2008) Infusion Reactions Triggered by Monoclonal Antibodies Treating Solid Tumors. Journal of Infusion Nursing 31:2, pages 74-83.
Crossref
Crossref
Zhen-wei Cai, Yongzheng Zhang, Robert M. Borzilleri, Ligang Qian, Stephanie Barbosa, Donna Wei, Xiaoping Zheng, Lawrence Wu, Junying Fan, Zhongping Shi, Barri S. Wautlet, Steve Mortillo, Robert JeyaseelanSr.Sr., Daniel W. Kukral, Amrita Kamath, Punit Marathe, Celia D’Arienzo, George Derbin, Joel C. Barrish, Jeffrey A. Robl, John T. Hunt, Louis J. Lombardo, Joseph Fargnoli & Rajeev S. Bhide. (2008)
Discovery of Brivanib Alaninate ((
S
)-((
R
)-1-(4-(4-Fluoro-2-methyl-1
H
-indol-5-yloxy)-5-methylpyrrolo[2,1-
f
][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
. Journal of Medicinal Chemistry 51:6, pages 1976-1980.
Crossref
Crossref
Chien-Fu Hung, Archana Monie & T. -C. Wu. 2008. Angiogenesis. Angiogenesis
451
460
.
Saburo Sone & Seiji Yano. (2007) Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone. Cancer and Metastasis Reviews 26:3-4, pages 685-689.
Crossref
Crossref
Simon Ekman, Michael Bergqvist, Carl-Henrik Heldin & Johan Lennartsson. (2007) Activation of Growth Factor Receptors in Esophageal Cancer—Implications for Therapy. The Oncologist 12:10, pages 1165-1177.
Crossref
Crossref
Hagop Youssoufian, Daniel J. Hicklin & Eric K. Rowinsky. (2007) Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy. Clinical Cancer Research 13:18, pages 5544s-5548s.
Crossref
Crossref
A Papapetropoulos. (2007)
A ginseng-derived oestrogen receptor
β
(ER
β
) agonist, Rb1 ginsenoside, attenuates capillary morphogenesis
. British Journal of Pharmacology 152:2, pages 172-174.
Crossref
Crossref
Yuquan Xu, Jixun Zhan, E. M. Kithsiri Wijeratne, Anna M. Burns, A. A. Leslie Gunatilaka & István Molnár. (2007)
Cytotoxic and Antihaptotactic Beauvericin Analogues from Precursor-Directed Biosynthesis with the Insect Pathogen
Beauveria bassiana
ATCC 7159
. Journal of Natural Products 70:9, pages 1467-1471.
Crossref
Crossref
Quoc T. Ho & Calvin J. Kuo. (2007) Vascular endothelial growth factor: Biology and therapeutic applications. The International Journal of Biochemistry & Cell Biology 39:7-8, pages 1349-1357.
Crossref
Crossref
T Kamba & D M McDonald. (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer 96:12, pages 1788-1795.
Crossref
Crossref